We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Feasibility Study Supports Use of Immunomagnetic Approach to Study Circulating Cancer Cells

By LabMedica International staff writers
Posted on 01 Apr 2015
Print article
Image: In the immunomagnetic approach, circulating cancer cells are attracted by specific biomarkers to bind to an array of micromagnets for further analyses (Photo courtesy of Dartmouth College).
Image: In the immunomagnetic approach, circulating cancer cells are attracted by specific biomarkers to bind to an array of micromagnets for further analyses (Photo courtesy of Dartmouth College).
Cancer researchers have combined the strength of magnetic separation with the specificity of immunochemical biomarker recognition to demonstrate the feasibility of capturing and analyzing rare circulating cells from the blood stream of cancer patients.

Writing in the March 4, 2015, online edition of the journal Scientific Reports, investigators at Dartmouth College (NH, USA) described a two-dimensional micromagnet array that they used to characterize generation of the magnetic field and to quantify the impact of micromagnets on rare cell separation. In this paper, they presented a theoretical framework and technical approach to implement microscale magnetic immunoassay through modulating the local magnetic field towards enhanced capture and distribution of rare cancer cells.

"The concept is to use novel cell-machine interfaces, integrated sensing, actuation, and biomarker recognition functionalities to isolate these rare cells (one per billion hematologic cells) from whole blood to determine malignancy unambiguously," said senior author Dr. John X.J Zhang, professor of engineering at Dartmouth College. "We will base the quantitative assessment on multiple tumor markers. This project demonstrates that a relatively simple blood test may eventually be able to provide unambiguous information to doctors about particular cancers in individuals."

The investigators found that there was good agreement between their theory and results of experiments using a human colon cancer cell line (COLO205) as the capture targets.

Related Links:

Dartmouth College


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.